Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind vehicle-controlled study of HY-072808 ointment in mild to moderate atopic dermatitis
CTR20234037Phase 3Active
- Sponsor
- Hefei Yigong Pharmaceutical
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing HY-072808 4% ointment with Vehicle control ointment (2 arms). Primary endpoints: Proportion of participants achieving IGA success at Day 29 and Proportion of participants achieving EASI 75 at Day 29. Started Apr 2024; status: active.
02
Drugs
HY-072808
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20234037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20234037.